Zacks: Brokerages Expect Synthetic Biologics, Inc (SYN) to Announce -$0.64 EPS

Equities analysts expect Synthetic Biologics, Inc (NASDAQ:SYN) to report earnings per share of ($0.64) for the current quarter, Zacks reports. Zero analysts have provided estimates for Synthetic Biologics’ earnings. Synthetic Biologics posted earnings per share of ($0.70) during the same quarter last year, which would suggest a positive year over year growth rate of 8.6%. The company is scheduled to issue its next quarterly earnings report on Tuesday, May 14th.

On average, analysts expect that Synthetic Biologics will report full-year earnings of ($2.48) per share for the current financial year. For the next year, analysts forecast that the firm will post earnings of ($2.54) per share. Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that that provide coverage for Synthetic Biologics.

Separately, William Blair reaffirmed an “outperform” rating on shares of Synthetic Biologics in a research note on Thursday, February 28th.

Shares of NASDAQ SYN traded down $0.01 during mid-day trading on Monday, reaching $0.63. The company had a trading volume of 118,600 shares, compared to its average volume of 326,436. Synthetic Biologics has a 52 week low of $0.51 and a 52 week high of $12.95.

Synthetic Biologics Company Profile

Synthetic Biologics, Inc, a late-stage clinical company, develops therapeutics designed to preserve the microbiome to protect and restore the health of patients. Its lead product candidates are in Phase III development, such as SYN-004 that is designed to protect the gut microbiome from the effects of commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C.

Featured Article: How prevalent are 12b-1 fees?

Get a free copy of the Zacks research report on Synthetic Biologics (SYN)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Synthetic Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics and related companies with's FREE daily email newsletter.